Subscribe: Ganfyd - Recent changes [en]
http://ganfyd.org/index.php?title=Special:Recentchanges&feed=rss&submit=Read
Added By: Feedage Forager Feedage Grade A rated
Language: English
Tags:
december  https  line line  line  mlj  nowiki  older revision  pubmed  ref  revision revision  revision  user  ← older 
Rate this Feed
Rate this feedRate this feedRate this feedRate this feedRate this feed
Rate this feed 1 starRate this feed 2 starRate this feed 3 starRate this feed 4 starRate this feed 5 star

Comments (0)

Feed Details and Statistics Feed Statistics
Preview: Ganfyd - Recent changes [en]

Ganfyd - Recent changes [en]



Track the most recent changes to the wiki in this feed.



Last Build Date: Sun, 04 Dec 2016 12:10:15 GMT

 



Category:DNA polymerase inhibitors

Sun, 04 Dec 2016 11:32:04 GMT

Confusion possible

← Older revision Revision as of 11:32, 4 December 2016
(One intermediate revision not shown)
Line 1: Line 1:
-
 
[[Category:Antivirals]]
[[Category:Antivirals]]
 +
[[Category:cytotoxic drugs]]
 +
Agents of this class can be effective in quite different conditions as there are so many functions and types of DNA polymerases in biology. Drugs that act predominantly on non human DNA polymerases could be useful in infectious diseases and those that act on human DNA polymerases could be useful in human malignancy.



Category:Nonnucleoside polymerase inhibitors

Sun, 04 Dec 2016 11:24:54 GMT

Categorise

← Older revision Revision as of 11:24, 4 December 2016
Line 1: Line 1:
[[Category:Antivirals]]
[[Category:Antivirals]]
 +
[[Category:DNA polymerase inhibitors]]



Category:PARP inhibitors

Sun, 04 Dec 2016 11:24:18 GMT

Categorise

← Older revision Revision as of 11:24, 4 December 2016
Line 2: Line 2:
[[Category:Drug classes]]
[[Category:Drug classes]]
[[Category:Cytotoxic drugs]]
[[Category:Cytotoxic drugs]]
 +
[[Category:DNA polymerase inhibitors]]



Niraparib

Sun, 04 Dec 2016 11:00:18 GMT

Small molecule PARP inhibitor

New page

{{pharmacologyBox||MK4827, 2-[4-[ (3S)- piperidin-3-yl ]phenyl] indazole-7- carboxamide, niraparib tosylate; UNII-75KE12AY9U; MK-4827-tosylate; MK-4827 (tosylate); 75KE12AY9U; 1038915-73-9}}
[[Niraparib]] is an oral poly(adenosine diphosphate [ADP]-ribose) polymerase 1/2 inhibitor being developed to treat [[ovarian cancer]] and other malignancies[https://www.ncbi.nlm.nih.gov/sites/entrez?itool=abstractplus&db=pubmed&cmd=Retrieve&dopt=abstractplus&list_uids=27717299 Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, Fabbro M, Ledermann JA, Lorusso D, Vergote I, Ben-Baruch NE, Marth C, Mądry R, Christensen RD, Berek JS, Dørum A, Tinker AV, du Bois A, González-Martín A, Follana P, Benigno B, Rosenberg P, Gilbert L, Rimel BJ, Buscema J, Balser JP, Agarwal S, Matulonis UA. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. The New England journal of medicine. 2016 Oct.](Print-Electronic) . It's off target activity is predicted to include actions on [[deoxycytidine kinase]] which might limit combination therapy approaches[https://www.ncbi.nlm.nih.gov/sites/entrez?itool=abstractplus&db=pubmed&cmd=Retrieve&dopt=abstractplus&list_uids=27866910 Knezevic CE, Wright G, Remsing Rix LL, Kim W, Kuenzi BM, Luo Y, Watters JM, Koomen JM, Haura EB, Monteiro AN, Radu C, Lawrence HR, Rix U. Proteome-wide Profiling of Clinical PARP Inhibitors Reveals Compound-Specific Secondary Targets. Cell chemical biology. 2016 Nov.](Print-Electronic) ([http://dx.doi.org/10.1016/j.chembiol.2016.10.011 Link to article] – subscription may be required.).
.{{refsec}}
[[category:PARP inhibitors]]



Dominant interference

Sun, 04 Dec 2016 10:21:05 GMT

Definition

New page

{{geneticsBox}}
[[Dominant interference]] is where the mutant allele of a [[heterozygote]] codes for a protein that intefers with normal protein function. This is often seen if the protein product is a component of a multi-peptide protein complex.
[[category:genetics]]



Haploinsufficiency

Sun, 04 Dec 2016 10:18:08 GMT

definition

New page

{{GeneticsBox}}
[[Haploinsufficiency]] is where only about 50% of normal protein is produced if the [[heterozygote]] gene involved is a member of the [[exome]].
[[category:genetics]]



Heterozygote

Sun, 04 Dec 2016 10:14:14 GMT

Redirect

New page

#REDIRECT[[homozygous]]



Heterozygosity

Sun, 04 Dec 2016 10:12:30 GMT

Deredirect

← Older revision Revision as of 10:12, 4 December 2016
Line 1: Line 1:
-
#REDIRECT[[homozygous]]
+
{{SubjectBox}}
 +
A [[heterozygote]] presenting with a disease [[phenotype]] has one wild-type [[allele]] and one mutant allele. Such [[heterozygosity]] can cause disease compared to normal because of:
 +
#[[Haploinsufficiency]]
 +
#*Only about 50% of normal protein is produced if the gene involved is a member of the [[exome]]
 +
#[[Dominant interference]]
 +
#*The mutant allele of the [[exome]] codes for a protein that intefers with normal protein function. This is often seen if the protein product is a component of a multi-peptide protein complex.
 +
#Creation of a new gene regulatory pattern.
 +
#*The mutant protein might interfere or activate pathways that original product has evolved not to interact with (many regulatory proteins are members of protein families with similar or even opposite actions)
 +
[[category:genetics]]
 +
[[category:clinical genetics]]



Exome

Sun, 04 Dec 2016 09:44:52 GMT

Relevance to human disease

← Older revision Revision as of 09:44, 4 December 2016
Line 1: Line 1:
-
The [[exome]] is the part of the genome of an organism that contain genes that are expressed. It is all the [[exon]]s.
+
The [[exome]] is the part of the genome of an organism that contain genes that are expressed. It is all the [[exon]]s. In man that's about 2% of the genome and errors cause about 60% of genetic diseases.
[[Category:Genetics]]
[[Category:Genetics]]
 +
[[Category:Clinical genetics]]



Help:Citations

Sun, 04 Dec 2016 01:26:02 GMT

More ← Older revision Revision as of 01:26, 4 December 2016 (3 intermediate revisions not shown)Line 25: Line 25: where '''refno''' is the [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed PUBMED] pmid reference number. where '''refno''' is the [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed PUBMED] pmid reference number. {{BiteBox| {{BiteBox| -This will generate automatically the full reference and a direct link, if it exists, to the article itself. Insert {{Refsec}} at the end of the article. Do check the ''Show Preview'' option, mainly as it takes a moment to download all those references first time from pubmed, so a server timeout could occur which is perhaps more recoverable through the browser back button, although bugs in the code are still possible :>}}+'''''''' ''refno'' '''''''' will generate automatically the full reference and a direct link, if it exists, to the article itself. Insert {{Refsec}} at the end of the article. Do check the ''Show Preview'' option, to check you have the syntax right. It takes a moment to download all those references first time from the Cambridge University based database we now use for technical reasons and convert them to https pubmed links, so a server timeout could occur.  This is perhaps recoverable through the browser back button on desktop browsers. Bugs in the code are still possible : >}} * Consider using '''''' ''refno'' '''''' which allows multiple same pmid references on a page to be summarised in the reference list. * Consider using '''''' ''refno'' '''''' which allows multiple same pmid references on a page to be summarised in the reference list. The preferred ''manual'' house style syntax is:   The preferred ''manual'' house style syntax is:   *'''[[pubmed:refno|Reference details]]''' *'''[[pubmed:refno|Reference details]]''' -If you reference an article before pubmed has indexed it you may mark it with the '''{{NoLinkYet}}''' template like   -*'''{{NoLinkYet}}Reference details'''  ====Why longer syntax might be better==== ====Why longer syntax might be better==== The syntax The syntax Line 114: Line 112: == What about content you cannot find a reference for? == == What about content you cannot find a reference for? == -Put '''{{Fact}}''' at the end of the statement you need to qualify with a reference. This shows other contributors that a reference or citation is needed.+Put '''{{Fact}}''' at the end of the statement you need to qualify with a reference. You get: {{Fact}} This shows other contributors that a reference or citation is needed. Consider that you can write in line code that it is not displayed but viewable by source. So this text is invisible but useful [...]



Help:Pubmed

Sun, 04 Dec 2016 00:48:43 GMT

Update

← Older revision Revision as of 00:48, 4 December 2016
Line 3: Line 3:
# Consider using '''''' ''refno'' '''''' which allows multiple same pmid references on a page to be summarised in the reference list.
# Consider using '''''' ''refno'' '''''' which allows multiple same pmid references on a page to be summarised in the reference list.
#At the end of the article insert ''' {{Refsec}} '''
#At the end of the article insert ''' {{Refsec}} '''
-
{{WarningBox|The syntax and old PubMed references may fail at some date after 31st December 2016 when PubMed removes http redirection to https}}
+
{{WarningBox|The generated syntax for old PubMed references may fail at some date after 31st December 2016 if PubMed removes http redirection to https. This is probably addressable by one of the administrators creating a BOT to clean up the thousands of old references. But since the whole web faces this issue hopefully http redirection will stay in place for some time. }}
More details are given in [[Help:Citations|Use of citations]].
More details are given in [[Help:Citations|Use of citations]].



Finasteride

Sun, 04 Dec 2016 00:36:43 GMT

Side effects

← Older revision Revision as of 00:36, 4 December 2016
Line 15: Line 15:
*5mg daily
*5mg daily
-
 
+
===Side-effects===
 +
*Blockage sex hormones
 +
*Orthostatic hypotension
May be used concurrently with [[:Category:Alphablockers|alphablockers]]
May be used concurrently with [[:Category:Alphablockers|alphablockers]]
{{refsec}}
{{refsec}}
[[Category:5alpha-reductase inhibitors]]
[[Category:5alpha-reductase inhibitors]]



Dutasteride

Sun, 04 Dec 2016 00:35:23 GMT

Neuroprotective? ← Older revision Revision as of 00:35, 4 December 2016 Line 5: Line 5: ===Introduction=== ===Introduction=== The enzyme [[3-oxo-5-alpha-steroid 4-dehydrogenase|5 α reductase]] metabolises [[testosterone]] to the more potent androgen, dihydrotestosterone.   The enzyme [[3-oxo-5-alpha-steroid 4-dehydrogenase|5 α reductase]] metabolises [[testosterone]] to the more potent androgen, dihydrotestosterone.   -Inhibition of this testosterone metabolism leads to reduction in prostate size, with improvement in urinary flow rate and in obstructive symptoms. There is some evidence that it inhibits growth of preexisting hormone responsive [[prostate cancer]][http://www.ncbi.nlm.nih.gov/sites/entrez?itool=abstractplus&db=pubmed&cmd=Retrieve&dopt=abstractplus&list_uids=20357281  Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, Pettaway CA, Tammela TL, Teloken C, Tindall DJ, Somerville MC, Wilson TH, Fowler IL, Rittmaster RS. Effect of dutasteride on the risk of prostate cancer. The New England journal of medicine. 2010 Apr 1; 362(13):1192-202.]([http://dx.doi.org/10.1056/NEJMoa0908127 Link to article] – subscription may be required.).Neither [[finasteride]] or [[dutasteride]] are recommended for prophylaxis of [[prostate cancer]] as while these drugs reduce the risk of very low-risk cancers (Gleason score 6 and below), they are associated with an absolute increase in tumours with a Gleason score of 8 to 10[http://www.ncbi.nlm.nih.gov/sites/entrez?itool=abstractplus&db=pubmed&cmd=Retrieve&dopt=abstractplus&list_uids=21675880  Theoret MR, Ning YM, Zhang JJ, Justice R, Keegan P, Pazdur R. The Risks and Benefits of 5α-Reductase Inhibitors for Prostate-Cancer Prevention. The New England journal of medicine. 2011 Jun 15.](Epub ahead of print) ([http://dx.doi.org/10.1056/NEJMp1106783 Link to article] – subscription may be required.)+Inhibition of this testosterone metabolism leads to reduction in prostate size, with improvement in urinary flow rate and in obstructive symptoms. There is some evidence that it inhibits growth of preexisting hormone responsive [[prostate cancer]][http://www.ncbi.nlm.nih.gov/sites/entrez?itool=abstractplus&db=pubmed&cmd=Retrieve&dopt=abstractplus&list_uids=20357281  Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, Pettaway CA, Tammela TL, Teloken C, Tindall DJ, Somerville MC, Wilson TH, Fowler IL, Rittmaster RS. Effect of dutasteride on the risk of prostate cancer. The New England journal of medicine. 2010 Apr 1; 362(13):1192-202.]([http://dx.doi.org/10.1056/NEJMoa0908127 Link to article] – subscription may be required.).Neither [[finasteride]] or [[dutasteride]] are recommended for prophylaxis of [[prostate cancer]] as while these drugs reduce the risk of very low-risk cancers (Gleason score 6 and below), they are associated with an absolute increase in tumours with a Gleason score of 8 to 10[http://www.ncbi.nlm.nih.gov/sites/entrez?itool=abstractplus&db=pubmed&cmd=Retrieve&dopt=abstractplus&list_uids=21675880  Theoret MR, Ning YM, Zhang JJ, Justice R, Keegan P, Pazdur R. The Risks and Benefits of 5α-Reductase Inhibitors for Prostate-Cancer Prevention. The New England journal of medicine. 2011 Jun 15.](Epub ahead of print) ([http://dx.doi.org/10.1056/NEJMp1106783 Link to article] – subscription may be required.)



Familial Parkinsons's disease

Sat, 03 Dec 2016 23:16:55 GMT

updated referebce to pmid format now its working again ← Older revision Revision as of 23:16, 3 December 2016 Line 9: Line 9: !style="background:#dff9d9;" align="left" |Monogenetic autosomal dominant !style="background:#dff9d9;" align="left" |Monogenetic autosomal dominant |style="background:#e9f9f9;" align="left" | |style="background:#e9f9f9;" align="left" | -|style="background:#dff9d9;" align="left" |[[SNCA]] (missense mutations or dublication)
[[LRRK2]] (found in 4% monogenetic parkinsons, missense mutations - usually Gly2019Ser)
[[VPS35]] ((codes an [[endosome]] protein - missense mutation Asp620Asn)
[[EIF4G1]] (missense mutations)
[[DNAJC13]] (codes an [[endosome]] traffiking protein - missense mutation Asn855Ser)
[[CHCHD2]] (missense mutations or splice-site alteration)
[[TMEM230]] (encodes a transmembrane protein of secretory/recycling vesicles, including synaptic vesicles in neurons. Disease-linked TMEM230 mutants impair synaptic vesicle trafficking)[https://www.ncbi.nlm.nih.gov/pubmed/27270108 Deng HX, Shi Y, Yang Y et al. Identification of TMEM230 mutations in familial Parkinson's disease. Nat Genet. 2016 Jul;48(7):733-9. doi: 10.1038/ng.3589. Epub 2016 Jun 6.]+|style="background:#dff9d9;" align="left" |[[SNCA]] (missense mutations or dublication)
[[LRRK2]] (found in 4% monogenetic parkinsons, missense mutations - usually Gly2019Ser)
[[VPS35]] ((codes an [[endosome]] protein - missense mutation Asp620Asn)
[[EIF4G1]] (missense mutations)
[[DNAJC13]] (codes an [[endosome]] traffiking protein - missense mutation Asn855Ser)
[[CHCHD2]] (missense mutations or splice-site alteration)
[[TMEM230]] (encodes a transmembrane protein of secretory/recycling vesicles, including synaptic vesicles in neurons. Disease-linked TMEM230 mutants impair synaptic vesicle trafficking)[https://www.ncbi.nlm.nih.gov/sites/entrez?itool=abstractplus&db=pubmed&cmd=Retrieve&dopt=abstractplus&list_uids=27270108 Deng HX, Shi Y, Yang Y, Ahmeti KB, Miller N, Huang C, Cheng L, Zhai H, Deng S, Nuytemans K, Corbett NJ, Kim MJ, Deng H, Tang B, Yang Z, Xu Y, Chan P, Huang B, Gao XP, Song Z, Liu Z, Fecto F, Siddique N, Foroud T, Jankovic J, Ghetti B, Nicholson DA, Krainc D, Melen O, Vance JM, Pericak-Vance MA, Ma YC, Rajput AH, Siddique T. Identification of TMEM230 mutations in familial Parkinson's disease. Nature genetics. 2016 Jul; 48(7):733-739.](Print-Electronic) ([http://dx.doi.org/10.1038/ng.3589 Link to article] – subscription may be required.) |----- |----- !style="background:#effeef;" align="left" |Monogenetic autosomal recessive !style="background:#effeef;" align="left" |Monogenetic autosomal recessive [...]



Talk:Safety netting

Sat, 03 Dec 2016 23:13:50 GMT

citations back working ← Older revision Revision as of 23:13, 3 December 2016 Line 1: Line 1: I can't work out why citations are not appearing below the refsec bit... --[[User:Penglish|Penglish]] 14:51, 30 November 2016 (UTC) I can't work out why citations are not appearing below the refsec bit... --[[User:Penglish|Penglish]] 14:51, 30 November 2016 (UTC) -.Sorry you have to do them manually as pmid has been broken by the Yanks demanding that all access to their government websites from end of year is https for the information download. You can always hope Trump gets his pet owned Congress and Senate to reverse this decision but I have little evidence that politicians really promote evidenced based decision making....and actually some time the website should move to https if someone can afford the price of the security certs. The easiest fix is probably an operating system upgrade. This is because the special php module was not needed back when website got going as and there is an awful lot of other stuff past its sell buy date over a decade on22:24, 30 November 2016 (UTC) .+:Sorry you have to do them manually as pmid has been broken by the Yanks demanding that all access to their government websites from end of year is https for the information download. You can always hope Trump gets his pet owned Congress and Senate to reverse this decision but I have little evidence that politicians really promote evidenced based decision making....and actually some time the website should move to https if someone can afford the price of the security certs. The easiest fix is probably an operating system upgrade. This is because the special php module was not needed back when website got going as and there is an awful lot of other stuff past its sell buy date over a decade on22:24, 30 November 2016 (UTC) -:We could add a LetsEncrypt certificate for https, but I'm wary of doing it on this creaky setup. It works well on defoam.net though [[User:Midgley|Midgley]] 00:32, 2 December 2016 (UTC)+::Citations back working - I had an idea on how to bypass Yanks and while EU remains intact but distracted it just might work for a while as EU politicians not yet ready to tell all sponsored websites to use https or else [[User:Mlj|Mlj]] 23:13, 3 December 2016 (UTC). -::Suspect typo \ for / compounded the issue for Peter :-) [[User:Mlj|Mlj]] 16:02, 3 December 2016 (UTC)+:::We could add a LetsEncrypt certificate for https, but I'm wary of doing it on this creaky setup. It works well on defoam.net though [[User:Midgley|Midgley]] 00:32, 2 December 2016 (UTC)  +::::Suspect typo \ for / compounded the issue for Peter :-) [[User:Mlj|Mlj]] 16:02, 3 December 2016 (UTC) [...]



Talk:Main Page

Sat, 03 Dec 2016 23:08:19 GMT

pmid caption finder back working ← Older revision Revision as of 23:08, 3 December 2016 Line 162: Line 162: ::: There is no need to be nervous.  Moving to a new server will be straightforward.  LAMP is bread & butter stuff.  I've done dummy runs on increasingly modern distros a few times - sadly, we've never followed through and got new (possibly virtual) hardware.  Optionally, we could move away from Apache to a more efficient server - I think Wikimedia use lighttpd.  A new server will offer superior performance at less cost. —[[User:Rupert|Rupert]] ([[User talk:Rupert|Talk]]) 16:41, 29 October 2016 (BST) ::: There is no need to be nervous.  Moving to a new server will be straightforward.  LAMP is bread & butter stuff.  I've done dummy runs on increasingly modern distros a few times - sadly, we've never followed through and got new (possibly virtual) hardware.  Optionally, we could move away from Apache to a more efficient server - I think Wikimedia use lighttpd.  A new server will offer superior performance at less cost. —[[User:Rupert|Rupert]] ([[User talk:Rupert|Talk]]) 16:41, 29 October 2016 (BST) ::::Looks like our pubmed_caption_finder is now broken courtesy of pubmed removing their http redirect to https on their back room server. I may have time later to see if Apache fix above works but doubt it. [[User:Mlj|Mlj]] 10:18, 6 November 2016 (UTC) ::::Looks like our pubmed_caption_finder is now broken courtesy of pubmed removing their http redirect to https on their back room server. I may have time later to see if Apache fix above works but doubt it. [[User:Mlj|Mlj]] 10:18, 6 November 2016 (UTC)  +:::::pubmed_caption_finder is now back working. I have done an awful hack using http://europepmc.org/ for source of article details but their RESTful backend is still http so we have all functionality back except ability to flag in red retracted papers. Identified a few code improvements that could be made to the pHp for greater efficiency but did not bother once I identified that at present not all perfect with europepmc server software serving up full articles. [[User:Mlj|Mlj]] 23:08, 3 December 2016 (UTC) == System Admin == == System Admin == [...]



Fatty acids

Sat, 03 Dec 2016 16:46:26 GMT

Typo ← Older revision Revision as of 16:46, 3 December 2016 Line 20: Line 20: Long-chain ω-3 polyunsaturated fatty acids (PUFAs) do not modulate [[psychosis]] risk in man as has been postulated to occur[http://jamanetwork.com/journals/jamapsychiatry/fullarticle/2587077 McGorry PD, Nelson B, Markulev C, et al. Effect of ω-3 Polyunsaturated Fatty Acids in Young People at Ultrahigh Risk for Psychotic Disorders. The NEURAPRO Randomized Clinical Trial JAMA Psychiatry 2016 doi:10.1001/jamapsychiatry.2016.2902].   Long-chain ω-3 polyunsaturated fatty acids (PUFAs) do not modulate [[psychosis]] risk in man as has been postulated to occur[http://jamanetwork.com/journals/jamapsychiatry/fullarticle/2587077 McGorry PD, Nelson B, Markulev C, et al. Effect of ω-3 Polyunsaturated Fatty Acids in Young People at Ultrahigh Risk for Psychotic Disorders. The NEURAPRO Randomized Clinical Trial JAMA Psychiatry 2016 doi:10.1001/jamapsychiatry.2016.2902].   ===Trans Fatty Acids=== ===Trans Fatty Acids=== -Technically its the artificial [[trans fats|''trans''-unsaturated fatty acids]] that you have to worry about (the proportion of trans fatty acids used in cooking oil are limited by law in Denmark and some states in America[http://www.nyc.gov/html/doh/html/cardio/cardio-transfat-healthcode.shtml New York City regulations on trans fatty acids]). The Australian Medical Association has also called for a ban.[http://www.ama.com.au/web.nsf/doc/WEEN-6VTUR5 Australian Medical Association press release]+Technically its the artificial [[trans fats|''trans''-unsaturated fatty acids]] that you have to worry about (the proportion of trans fatty acids used in cooking oil are limited by law in Denmark and some states in America[http://www.nyc.gov/html/doh/html/cardio/cardio-transfat-healthcode.shtml New York City regulations on trans fatty acids]. The Australian Medical Association has also called for a ban.[http://www.ama.com.au/web.nsf/doc/WEEN-6VTUR5 Australian Medical Association press release] {{refsec}} {{refsec}} [...]



Omega-3 fatty acids

Sat, 03 Dec 2016 16:44:37 GMT

← Older revision Revision as of 16:44, 3 December 2016
(One intermediate revision not shown)
Line 1: Line 1:
{{EtymologyBox|The name derives from chemical nomenclature. The first carbon adjacent to the carboxyl group is designated alpha (α) while omega (ω) refers to the very last carbon atom regardless of the length of the carbon chain. Omega-3 in the context of fatty acids refers to the presence of a carbon double-bond at the 3rd carbon from the end. See also ''[[Greek alphabet]]''.}}
{{EtymologyBox|The name derives from chemical nomenclature. The first carbon adjacent to the carboxyl group is designated alpha (α) while omega (ω) refers to the very last carbon atom regardless of the length of the carbon chain. Omega-3 in the context of fatty acids refers to the presence of a carbon double-bond at the 3rd carbon from the end. See also ''[[Greek alphabet]]''.}}
-
'''Omega-3 [[fatty acids]]''' is the popular name for '''n-3 polyunsaturated fatty acids''' as found in [[oily fish]].  As well as being essential dietary components as they can not be synthesised in man ''de novo'', they can also be used as therapeutic agents, particularly where the diet is deficient.
+
'''Omega-3 [[fatty acids]]''', '''omega-3 polyunsaturated [[fatty acids]]''' and '''ω-3 PUFAs''' are popular names for '''n-3 polyunsaturated fatty acids''' as found in [[oily fish]].  As well as being essential dietary components as they can not be synthesised in man ''de novo'', they can also be used as therapeutic agents, particularly where the diet is deficient.
{{KeyPointsBox|
{{KeyPointsBox|
*Marine food source - GOOD as contains DHA
*Marine food source - GOOD as contains DHA



Drug trials

Sat, 03 Dec 2016 16:09:20 GMT

Reference ← Older revision Revision as of 16:09, 3 December 2016 Line 28: Line 28: *These involve [[randomised controlled trial]]s *These involve [[randomised controlled trial]]s *Usually for regulatory purposes the standard for efficacy is against [placebo]] *Usually for regulatory purposes the standard for efficacy is against [placebo]] -*Non-inferiority trials may be done to compare a new (trial) treatment to existing treatments, to ensure it works at least as well.ERROR: Unable to contact Pubmed. This may be transient - please try again later. If this error recurs, please contact a ganfyd admin.(for PMID: 23227058 ) ("''Non-inferior'' (in quality) to" = "not lower quality than" = "at least as good as"".+*Non-inferiority trials may be done to compare a new (trial) treatment to existing treatments, to ensure it works at least as well.[https://www.ncbi.nlm.nih.gov/pubmed/?term=23227058 Hahn S. Understanding noninferiority trials. Korean J Pediatr. 2012 Nov;55(11):403-7. doi: 10.3345/kjp.2012.55.11.403. Epub 2012 Nov 23] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3510268/ link to article]. ("''Non-inferior'' (in quality) to" = "not lower quality than" = "at least as good as"". *There may be trials against a gold standard or against similar drugs if issues of better efficacy are important.   *There may be trials against a gold standard or against similar drugs if issues of better efficacy are important.   *Concept of clinical equipoise. *Concept of clinical equipoise. [...]



Talk:Safety netting

Sat, 03 Dec 2016 16:02:15 GMT

Typos

← Older revision Revision as of 16:02, 3 December 2016
Line 2: Line 2:
.Sorry you have to do them manually as pmid has been broken by the Yanks demanding that all access to their government websites from end of year is https for the information download. You can always hope Trump gets his pet owned Congress and Senate to reverse this decision but I have little evidence that politicians really promote evidenced based decision making....and actually some time the website should move to https if someone can afford the price of the security certs. The easiest fix is probably an operating system upgrade. This is because the special php module was not needed back when website got going as and there is an awful lot of other stuff past its sell buy date over a decade on22:24, 30 November 2016 (UTC) .
.Sorry you have to do them manually as pmid has been broken by the Yanks demanding that all access to their government websites from end of year is https for the information download. You can always hope Trump gets his pet owned Congress and Senate to reverse this decision but I have little evidence that politicians really promote evidenced based decision making....and actually some time the website should move to https if someone can afford the price of the security certs. The easiest fix is probably an operating system upgrade. This is because the special php module was not needed back when website got going as and there is an awful lot of other stuff past its sell buy date over a decade on22:24, 30 November 2016 (UTC) .
:We could add a LetsEncrypt certificate for https, but I'm wary of doing it on this creaky setup. It works well on defoam.net though [[User:Midgley|Midgley]] 00:32, 2 December 2016 (UTC)
:We could add a LetsEncrypt certificate for https, but I'm wary of doing it on this creaky setup. It works well on defoam.net though [[User:Midgley|Midgley]] 00:32, 2 December 2016 (UTC)
 +
::Suspect typo \ for / compounded the issue for Peter :-) [[User:Mlj|Mlj]] 16:02, 3 December 2016 (UTC)



Safety netting

Sat, 03 Dec 2016 16:00:00 GMT

← Older revision Revision as of 16:00, 3 December 2016 (One intermediate revision not shown)Line 1: Line 1: -{{stub}}+{{SubjectBox}} Safety netting is an expression used in medical circles. It is used when a patient has been seen who is unlikely - but not certain not - to have a serious condition. Safety netting is an expression used in medical circles. It is used when a patient has been seen who is unlikely - but not certain not - to have a serious condition. Line 11: Line 11: So, safety netting is about acknowledging that some patients don't recover as expected, and ensuring that - when it starts to become apparent that this is happening - the patient or their parents/carers take appropriate action promptly. It's not always an easy line to tread: you want to reassure the patient appropriately, while still ensuring that they are not complacent if things start to go wrong. So, safety netting is about acknowledging that some patients don't recover as expected, and ensuring that - when it starts to become apparent that this is happening - the patient or their parents/carers take appropriate action promptly. It's not always an easy line to tread: you want to reassure the patient appropriately, while still ensuring that they are not complacent if things start to go wrong. -There is a [[Commissioning for Quality and Innovation (CQUINs) payments framework|CQUIN]] about early recognition of sepsis.[https://www.england.nhs.uk/wp-content/uploads/2016/03/cquin-guidance-16-17-v3.pdf NHS England. ''Commissioning for Quality and Innovation (CQUIN): Guidance for 2016/17.'' 2016(March).]+There is a [[Commissioning for Quality and Innovation (CQUINs) payments framework|CQUIN]] about early recognition of sepsis.[https://www.england.nhs.uk/wp-content/uploads/2016/03/cquin-guidance-16-17-v3.pdf NHS England. 'Commissioning for Quality and Innovation (CQUIN): Guidance for 2016/17.' 2016(March).] Resources are available including: Resources are available including: *in the "Red Book" given to parents in England. *in the "Red Book" given to parents in England. -*the [http://www.whenshouldiworry.com/ "When should I worry" leaflet] from from the Cochrane Institute of Primary Care & Public Health, Cardiff University School of Medicine.+*the [http://www.whenshouldiworry.com/ "When should I worry" leaflet][http://www.whenshouldiworry.com/ "When should I worry" leaflet] from from the Cochrane Institute of Primary Care & Public Health, Cardiff University School of Medicine. *from the [http://sepsistrust.org/ Sepsis Trust]. *from the [http://sepsistrust.org/ Sepsis Trust]. -*Many local leaflets etc. have also been produced.+*Many local leaflets etc. have also been produced -==References==  -The ganfyd references function seems to broken as I write...  {{Refsec}} {{Refsec}}  +{{draft}}  +[[category:primary care]][[category:emergency medicine]] [...]



Safety netting

Sat, 03 Dec 2016 15:04:24 GMT

← Older revision Revision as of 15:04, 3 December 2016
Line 19: Line 19:
*Many local leaflets etc. have also been produced.
*Many local leaflets etc. have also been produced.
-
{{refsec}}
+
==References==
 +
The ganfyd references function seems to broken as I write...
 +
 
 +
{{Refsec}}



Drug trials

Sat, 03 Dec 2016 15:01:21 GMT

← Older revision Revision as of 15:01, 3 December 2016 (2 intermediate revisions not shown)Line 28: Line 28: *These involve [[randomised controlled trial]]s *These involve [[randomised controlled trial]]s *Usually for regulatory purposes the standard for efficacy is against [placebo]] *Usually for regulatory purposes the standard for efficacy is against [placebo]] -*There may be trials against a gold standard or against similar drugs if issues of better efficacy are important.+*Non-inferiority trials may be done to compare a new (trial) treatment to existing treatments, to ensure it works at least as well.ERROR: Unable to contact Pubmed. This may be transient - please try again later. If this error recurs, please contact a ganfyd admin.(for PMID: 23227058 ) ("''Non-inferior'' (in quality) to" = "not lower quality than" = "at least as good as"".  +*There may be trials against a gold standard or against similar drugs if issues of better efficacy are important.   *Concept of clinical equipoise. *Concept of clinical equipoise. *If established treatment, new drug vs best treatment very rarely takes place as trial sizes have to be large, there can be problems obtaining cooperation of parties with an interest, and the risk of a result that might discourage product take up is high. *If established treatment, new drug vs best treatment very rarely takes place as trial sizes have to be large, there can be problems obtaining cooperation of parties with an interest, and the risk of a result that might discourage product take up is high. Line 35: Line 36: === Phase 4 Trials === === Phase 4 Trials === -*Post marketting+*Post marketing -*These can provide survillence function (will increasingly become compulsory following [[:Category:Coxib | Coxib]] problems.)+*These can provide surveillance function (will increasingly become compulsory following [[:Category:Coxib | Coxib]] problems.) *New indications mainly (it was Phase 4 trial of [[rofecoxib]] that lead to its [[Drug withdrawals|withdrawal from the market]] *New indications mainly (it was Phase 4 trial of [[rofecoxib]] that lead to its [[Drug withdrawals|withdrawal from the market]]  +  +{{Refsec}} [[Category: Evidence Based Healthcare]][[Category:Pharmacology]][[Category:Clinical pharmacology]] [[Category: Evidence Based Healthcare]][[Category:Pharmacology]][[Category:Clinical pharmacology]] [[Category:Clinical trials]] [[Category:Clinical trials]] [...]



Levodopa

Fri, 02 Dec 2016 22:36:43 GMT

typos ← Older revision Revision as of 22:36, 2 December 2016 (3 intermediate revisions not shown)Line 5: Line 5: ==Introduction== ==Introduction== -It gets metabolised to [[dopamine]] to work. Accordingly it is usually added to inhibitors of this conversion in the periphery to minimise dopaminergic side effects. These tend to be [[carbidopa]] (co-careldopa, Sinemet®) or [[benserazide]] (co-beneldopa), Madopar®). Is also marketed in various parts of the world combined with [[entacapone]] (eg Stalevo® or Sastravi®) or as a product for duodenal infusion(Duodopa®).+Levodopa (L-dopa) gets metabolised to [[dopamine]] to work (d-dopa is not converted into dopamine and causes [[neutropenia]]). Accordingly it is usually added to inhibitors of this conversion in the periphery to minimise dopaminergic side effects. These tend to be [[carbidopa]] ([[co-careldopa]], Sinemet®) or [[benserazide]] ([[co-beneldopa]], not marketed in USA, Madopar®). Is also marketed in various parts of the world combined with [[entacapone]] (eg Stalevo® or Sastravi®) or as a product for duodenal infusion(Duodopa®). ==Clinical Use== ==Clinical Use== Line 18: Line 18: Forget about the association with malignant [[melanoma]] and levodopa in the pharmacology literature, it has now been shown to be due to the Parkinson's disease, not the drug.[[Pubmed:17258651|Zanetti R, Rosso S. Levodopa and the risk of melanoma. Lancet 2007;369:257-8.]] ([http://dx.doi.org/10.1016/S0140-6736(07)60125-1 Direct link] – subscription may be required.)    Forget about the association with malignant [[melanoma]] and levodopa in the pharmacology literature, it has now been shown to be due to the Parkinson's disease, not the drug.[[Pubmed:17258651|Zanetti R, Rosso S. Levodopa and the risk of melanoma. Lancet 2007;369:257-8.]] ([http://dx.doi.org/10.1016/S0140-6736(07)60125-1 Direct link] – subscription may be required.)    ====Side effects==== ====Side effects====  +*Nausea and vomiting  +*Hallucinosis  +*Drowsiness ===Special advice=== ===Special advice=== ==Pharmacology== ==Pharmacology== ===History=== ===History=== -[[Arvid Carisson]] had to wait until [[2000]] to get the [[Nobel prize]] for "''proving that dopamine is a neurotransmitter in the brain whose depletion leads to symptoms of Parkinson's disease''".+[[Arvid Carisson]] had to wait until [[2000]] to get the [[Nobel prize]] for "''proving that dopamine is a neurotransmitter in the brain whose depletion leads to symptoms of Parkinson's disease''". Birkmayer published in an obscure journal in [[1961]] and also had issues with his collaborators delaying worldwide access to this advance by about 6 years. However it is unclear if such a drug with apparently a low therapeutic index and such challenging in dosing would get through the development process today any quicker or at all.
Parkinson's disease

Fri, 02 Dec 2016 21:34:37 GMT

had't noticed table of genetic causes out of date ← Older revision Revision as of 21:34, 2 December 2016 Line 21: Line 21: !style="background:#dff9d9;" align="left" |Monogenetic autosomal dominant !style="background:#dff9d9;" align="left" |Monogenetic autosomal dominant |style="background:#e9f9f9;" align="left" | |style="background:#e9f9f9;" align="left" | -|style="background:#dff9d9;" align="left" |[[SNCA]] (missense mutations or dublication)
[[LRRK2]] (found in 4% monogenetic parkinsons, missense mutations - usually Gly2019Ser)
[[VPS35]] ((codes an [[endosome]] protein - missense mutation Asp620Asn)
[[EIF4G1]] (missense mutations)
[[DNAJC13]] (codes an [[endosome]] traffiking protein - missense mutation Asn855Ser)
[[CHCHD2]] (missense mutations or splice-site alteration)  +|style="background:#dff9d9;" align="left" |[[SNCA]] (missense mutations or dublication)
[[LRRK2]] (found in 4% monogenetic parkinsons, missense mutations - usually Gly2019Ser)
[[VPS35]] ((codes an [[endosome]] protein - missense mutation Asp620Asn)
[[EIF4G1]] (missense mutations)
[[DNAJC13]] (codes an [[endosome]] traffiking protein - missense mutation Asn855Ser)
[[CHCHD2]] (missense mutations or splice-site alteration)
[[TMEM230]] (encodes a transmembrane protein of secretory/recycling vesicles, including synaptic vesicles in neurons. Disease-linked TMEM230 mutants impair synaptic vesicle trafficking)[https://www.ncbi.nlm.nih.gov/pubmed/27270108 Deng HX, Shi Y, Yang Y et al. Identification of TMEM230 mutations in familial Parkinson's disease. Nat Genet. 2016 Jul;48(7):733-9. doi: 10.1038/ng.3589. Epub 2016 Jun 6.] |----- |----- !style="background:#effeef;" align="left" |Monogenetic autosomal recessive !style="background:#effeef;" align="left" |Monogenetic autosomal recessive [...]



Familial Parkinsons's disease

Fri, 02 Dec 2016 21:31:48 GMT

create New page{{GeneticsBox}} {| class="wikitable" |+ Familial Parkinson's Disease |----- !style="background:#669966; color:#ffffff;" | Type !style="background:#6699cc; color:#ffffff;" | Environmental modulators !style="background:#669966; color:#ffffff;" | Genetic[https://www.ncbi.nlm.nih.gov/sites/entrez?itool=abstractplus&db=pubmed&cmd=Retrieve&dopt=abstractplus&list_uids=25064009 Nalls MA, Pankratz N, Lill CM, Do CB, Hernandez DG, Saad M, DeStefano AL, Kara E, Bras J, Sharma M, Schulte C, Keller MF, Arepalli S, Letson C, Edsall C, Stefansson H, Liu X, Pliner H, Lee JH, Cheng R, Ikram MA, Ioannidis JP, Hadjigeorgiou GM, Bis JC, Martinez M, Perlmutter JS, Goate A, Marder K, Fiske B, Sutherland M, Xiromerisiou G, Myers RH, Clark LN, Stefansson K, Hardy JA, Heutink P, Chen H, Wood NW, Houlden H, Payami H, Brice A, Scott WK, Gasser T, Bertram L, Eriksson N, Foroud T, Singleton AB. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. Nature genetics. 2014 Sep; 46(9):989-93.]([http://dx.doi.org/10.1038/ng.3043 Link to article] – subscription may be required.) |----- !style="background:#dff9d9;" align="left" |Monogenetic autosomal dominant |style="background:#e9f9f9;" align="left" | |style="background:#dff9d9;" align="left" |[[SNCA]] (missense mutations or dublication)
[[LRRK2]] (found in 4% monogenetic parkinsons, missense mutations - usually Gly2019Ser)
[[VPS35]] ((codes an [[endosome]] protein - missense mutation Asp620Asn)
[[EIF4G1]] (missense mutations)
[[DNAJC13]] (codes an [[endosome]] traffiking protein - missense mutation Asn855Ser)
[[CHCHD2]] (missense mutations or splice-site alteration)
[[TMEM230]] (encodes a transmembrane protein of secretory/recycling vesicles, including synaptic vesicles in neurons. Disease-linked TMEM230 mutants impair synaptic vesicle trafficking)[https://www.ncbi.nlm.nih.gov/pubmed/27270108 Deng HX, Shi Y, Yang Y et al. Identification of TMEM230 mutations in familial Parkinson's disease. Nat Genet. 2016 Jul;48(7):733-9. doi: 10.1038/ng.3589. Epub 2016 Jun 6.] |----- !style="background:#effeef;" align="left" |Monogenetic autosomal recessive |style="background:#f9f9ff;" align="left" | |style="background:#effeef;" align="left" |[[PARKIN]] (early onset monogenetic parkinsons - codes for mitochondrial protein involved in removing damaged mitochondria - exon rearrangements)
[[PINK1]] {codes for mitochondrial protein involved in removing damaged mitochondria -missense or nonsense mutations, sometimes exon deletion or dublication)
[[DJ-1]] ( protein may protect mitochondria from oxidative stress - missense mutations, exon rearrangements or rarely splice-site alerations)
[[VPS13C]] causes an early onset parkinsonism dementia presentation[https://www.ncbi.nlm.nih.gov/sites/entrez?itool=abstractplus&db=pubmed&cmd=Retrieve&dopt=abstractplus&list_uids=26942284 Lesage S, Drouet V, Majounie E, Deramecourt V, Jacoupy M, Nicolas A, Cormier-Dequaire F, Hassoun SM, Pujol C, Ciura S, Erpapazoglou Z, U[...]



Parkinson's disease

Fri, 02 Dec 2016 21:17:10 GMT

update ← Older revision Revision as of 21:17, 2 December 2016 Line 46: Line 46: ==Signs== ==Signs== Some use the acronym 'TRAP' Some use the acronym 'TRAP' -*Tremor - pill rolling tremor, predominantly at rest+*Tremor - pill rolling tremor, predominantly at rest 6-8Hz  +**Characteristically brought out by activity in the other limb and upper limb assymmetrical (in idiopathic parkinsons disease)  +**Does not involve the head *Rigidity - lead pipe or with tremor becomes cogwheel *Rigidity - lead pipe or with tremor becomes cogwheel *'''[[Akinesia]] or [[bradykinesia]]''' *'''[[Akinesia]] or [[bradykinesia]]'''  +**Must be present to make diagnosis according to Brain bank criteria. Further specialists look for fatigue in the bradykinesia as other conditions such as depression or cerebrovascular disease do not usually produce this *''Postural Instability'' *''Postural Instability'' -These are the cardinal signs of [[parkinsonism]] with bradykinesia being the key sign and postural instability depreciated due to its presence in many other common conditions that never strictly manifest parkinsonism.+These are the cardinal signs of [[parkinsonism]] with '''bradykinesia''' being the key sign and postural instability depreciated due to its presence in many other common conditions that never strictly manifest parkinsonism. In the early stages of Parkinson's disease, the signs are typically asymmetrical and most commonly affect the upper body. Symmetrical and/or lower body Parkinsonism should raise the possibility of an alternate diagnosis. In the early stages of Parkinson's disease, the signs are typically asymmetrical and most commonly affect the upper body. Symmetrical and/or lower body Parkinsonism should raise the possibility of an alternate diagnosis. Line 64: Line 67: *[[Micrographia]] *[[Micrographia]] -==Differential diagnosis==+==Diagnosis==  +Most specialists make the diagnosis by observation over time, which can be as short as a single consultation. Presently this luxury relative to other conditions exists as no licensed treatment is neuroprotective and there is no specific investigation for idiopathic parkinson's disease. This does not stop investigation, mainly to exclude other conditions.  +===Differential diagnosis=== *[[Multiple systems atrophy]] *[[Multiple systems atrophy]]  +**This is the major differential for specialists *[[Progressive supranuclear palsy]] *[[Progressive supranuclear palsy]] *[[Dementia with Lewy Bodies]] *[[Dementia with Lewy Bodies]] Line 77: Line 83: ==Investigations== ==Investigations== These are done for the exclusion of the wide range of other conditions that can cause or mimic [[Parkinsonism]]. While certain types of [[PET]] and [[imaging|SPECT]] scans can give consistent information, they do not add to the clinical formulation in most patients, so are not usefully routinely. A [[imaging|DAT]] scan can be useful in certain tremor presentations, as the initial differential diagnosis of patients presenting with parkinsonian tremor alone can be narrowed earlier than would otherwise be the case. These are done for the exclusion of the wide range of other conditions that can cause or mimic [[Parkinsonism]]. While certain types of [[PET]] and [[imaging|SPECT]] scans can give consistent information, they do not add to [...]



Pathological gambling

Fri, 02 Dec 2016 21:16:30 GMT

redirect

New page

#redirect[[Dopamine dysregulation syndrome]]



Talk:Safety netting

Fri, 02 Dec 2016 00:32:35 GMT

HTTPS

← Older revision Revision as of 00:32, 2 December 2016
Line 1: Line 1:
I can't work out why citations are not appearing below the refsec bit... --[[User:Penglish|Penglish]] 14:51, 30 November 2016 (UTC)
I can't work out why citations are not appearing below the refsec bit... --[[User:Penglish|Penglish]] 14:51, 30 November 2016 (UTC)
.Sorry you have to do them manually as pmid has been broken by the Yanks demanding that all access to their government websites from end of year is https for the information download. You can always hope Trump gets his pet owned Congress and Senate to reverse this decision but I have little evidence that politicians really promote evidenced based decision making....and actually some time the website should move to https if someone can afford the price of the security certs. The easiest fix is probably an operating system upgrade. This is because the special php module was not needed back when website got going as and there is an awful lot of other stuff past its sell buy date over a decade on22:24, 30 November 2016 (UTC) .
.Sorry you have to do them manually as pmid has been broken by the Yanks demanding that all access to their government websites from end of year is https for the information download. You can always hope Trump gets his pet owned Congress and Senate to reverse this decision but I have little evidence that politicians really promote evidenced based decision making....and actually some time the website should move to https if someone can afford the price of the security certs. The easiest fix is probably an operating system upgrade. This is because the special php module was not needed back when website got going as and there is an awful lot of other stuff past its sell buy date over a decade on22:24, 30 November 2016 (UTC) .
 +
:We could add a LetsEncrypt certificate for https, but I'm wary of doing it on this creaky setup. It works well on defoam.net though [[User:Midgley|Midgley]] 00:32, 2 December 2016 (UTC)



Safety netting

Fri, 02 Dec 2016 00:30:14 GMT

← Older revision Revision as of 00:30, 2 December 2016
Line 1: Line 1:
{{stub}}
{{stub}}
-
Safety netting is an expression used in medical circles. It is used when a patient has been seen who is unlikely - but not certain - to have a serious condition.
+
Safety netting is an expression used in medical circles. It is used when a patient has been seen who is unlikely - but not certain not - to have a serious condition.
Many people have minor, self-limiting viral illnesses. A doctor may be asked to assess a child with a mild fever, a bit snotty and sweaty, but nothing indicating serious illness. The doctor is competent, and up-to-date on the diagnosis of complications such as sepsis (see e.g. these articles
Many people have minor, self-limiting viral illnesses. A doctor may be asked to assess a child with a mild fever, a bit snotty and sweaty, but nothing indicating serious illness. The doctor is competent, and up-to-date on the diagnosis of complications such as sepsis (see e.g. these articles



Talk:Main Page

Fri, 02 Dec 2016 00:12:46 GMT

System Admin: PHP ← Older revision Revision as of 00:12, 2 December 2016 (One intermediate revision not shown)Line 154: Line 154: ::::::Sorry but from about 13:30 another outage with I assume again apache in a race condition with MySQL. Because of race condition took ages to respond to log into server and for server to process commands. Hard stop apache done to allow reboot. MySQL had a process Expect a 2 hour process to get it back up from when one of sysadmins detects issue. Roll on a rebuild. [[User:Mlj|Mlj]] 22:39, 20 October 2016 (BST) ::::::Sorry but from about 13:30 another outage with I assume again apache in a race condition with MySQL. Because of race condition took ages to respond to log into server and for server to process commands. Hard stop apache done to allow reboot. MySQL had a process Expect a 2 hour process to get it back up from when one of sysadmins detects issue. Roll on a rebuild. [[User:Mlj|Mlj]] 22:39, 20 October 2016 (BST) :::::::Sorry but the old apache race came back from about 14:00. Takes about an hour to reboot server once realised - and I had no console handy. [[User:Mlj|Mlj]] 23:44, 1 December 2016 (UTC) :::::::Sorry but the old apache race came back from about 14:00. Takes about an hour to reboot server once realised - and I had no console handy. [[User:Mlj|Mlj]] 23:44, 1 December 2016 (UTC)  +::::::::Thanks though.  I only got logged in as you brought it back up.  [[User:Midgley|Midgley]] 00:10, 2 December 2016 (UTC)  + ==pubmed_caption_finder== ==pubmed_caption_finder== This has to be updated given PubMed's shift to https from tomorrow. From today it will generate https references BUT  the module still uses http call in php (as https call not recognised) to get all the info. This will no doubt change and give us message "Unable to contact Pubmed. This may be transient - please try again later. If this error recurs, please contact a ganfyd admin." If in due course I can enable php to do https I have version 20 of the module uploaded and ready to go and replace present version 21 (we were on version 19 before today) Cheers[[User:Mlj|Mlj]] 18:37, 26 September 2016 (BST) This has to be updated given PubMed's shift to https from tomorrow. From today it will generate https references BUT  the module still uses http call in php (as https call not recognised) to get all the info. This will no doubt change and give us message "Unable to contact Pubmed. This may be transient - please try again later. If this error recurs, please contact a ganfyd admin." If in due course I can enable php to do https I have version 20 of the module uploaded and ready to go and replace present version 21 (we were on version 19 before today) Cheers[[User:Mlj|Mlj]] 18:37, 26 September 2016 (BST) Line 165: Line 167: ganfyd.co.uk and ganfyd.net are available as is medipaedia.  [[User:Midgley|Midgley]] 13:50, 29 October 2016 (BST) ganfyd.co.uk and ganfyd.net are available as is medipaedia.  [[User:Midgley|Midgley]] 13:50, 29 October 2016 (BST) :gives me an idea - see separate email [[User:Mlj|Mlj]] 23:16, 31 October 2016 (UTC) :gives me an idea - see separate email [[User:Mlj|Mlj]] 23:16, 31 October 2016 (UTC)  +:: P[...]



Talk:Main Page

Thu, 01 Dec 2016 23:44:57 GMT

Another outage ← Older revision Revision as of 23:44, 1 December 2016 Line 153: Line 153: :::::MySQL half went down again about 20:00 and while detected pretty smartly , mysql and apache seem to have conspired to create a mutual race condition, making reboot an unexpectedly delayed international effort taking about 3 hours. [[User:Midgley|Midgley's]] lost sleep, so users had minimum downtime, is regretted [[User:Mlj|Mlj]] 03:38, 23 August 2016 (BST) :::::MySQL half went down again about 20:00 and while detected pretty smartly , mysql and apache seem to have conspired to create a mutual race condition, making reboot an unexpectedly delayed international effort taking about 3 hours. [[User:Midgley|Midgley's]] lost sleep, so users had minimum downtime, is regretted [[User:Mlj|Mlj]] 03:38, 23 August 2016 (BST) ::::::Sorry but from about 13:30 another outage with I assume again apache in a race condition with MySQL. Because of race condition took ages to respond to log into server and for server to process commands. Hard stop apache done to allow reboot. MySQL had a process Expect a 2 hour process to get it back up from when one of sysadmins detects issue. Roll on a rebuild. [[User:Mlj|Mlj]] 22:39, 20 October 2016 (BST) ::::::Sorry but from about 13:30 another outage with I assume again apache in a race condition with MySQL. Because of race condition took ages to respond to log into server and for server to process commands. Hard stop apache done to allow reboot. MySQL had a process Expect a 2 hour process to get it back up from when one of sysadmins detects issue. Roll on a rebuild. [[User:Mlj|Mlj]] 22:39, 20 October 2016 (BST)  +:::::::Sorry but the old apache race came back from about 14:00. Takes about an hour to reboot server once realised - and I had no console handy. [[User:Mlj|Mlj]] 23:44, 1 December 2016 (UTC) ==pubmed_caption_finder== ==pubmed_caption_finder== This has to be updated given PubMed's shift to https from tomorrow. From today it will generate https references BUT  the module still uses http call in php (as https call not recognised) to get all the info. This will no doubt change and give us message "Unable to contact Pubmed. This may be transient - please try again later. If this error recurs, please contact a ganfyd admin." If in due course I can enable php to do https I have version 20 of the module uploaded and ready to go and replace present version 21 (we were on version 19 before today) Cheers[[User:Mlj|Mlj]] 18:37, 26 September 2016 (BST) This has to be updated given PubMed's shift to https from tomorrow. From today it will generate https references BUT  the module still uses http call in php (as https call not recognised) to get all the info. This will no doubt change and give us message "Unable to contact Pubmed. This may be transient - please try again later. If this error recurs, please contact a ganfyd admin." If in due course I can enable php to do https I have version 20 of the module uploaded and ready to go and replace present version 21 (we were on version 19 before today) Cheers[[User:Mlj|Mlj]] 18:37, 26 September 2016 (BST) [...]



Merseyside

Thu, 01 Dec 2016 08:06:00 GMT

Created page with "Neonatal blood spot screening - 0151 252 5489ꪪ"

New page

Neonatal blood spot screening - 0151 252 5489ꪪ



Talk:Safety netting

Wed, 30 Nov 2016 22:24:05 GMT

why - see talk main page

← Older revision Revision as of 22:24, 30 November 2016
Line 1: Line 1:
I can't work out why citations are not appearing below the refsec bit... --[[User:Penglish|Penglish]] 14:51, 30 November 2016 (UTC)
I can't work out why citations are not appearing below the refsec bit... --[[User:Penglish|Penglish]] 14:51, 30 November 2016 (UTC)
 +
.Sorry you have to do them manually as pmid has been broken by the Yanks demanding that all access to their government websites from end of year is https for the information download. You can always hope Trump gets his pet owned Congress and Senate to reverse this decision but I have little evidence that politicians really promote evidenced based decision making....and actually some time the website should move to https if someone can afford the price of the security certs. The easiest fix is probably an operating system upgrade. This is because the special php module was not needed back when website got going as and there is an awful lot of other stuff past its sell buy date over a decade on22:24, 30 November 2016 (UTC) .



Requests for work experience

Wed, 30 Nov 2016 20:18:01 GMT

tweak ← Older revision Revision as of 20:18, 30 November 2016 Line 1: Line 1: -Prospective applicants to medical school are often encouraged to gain some exposure or experience of medicine.+Prospective applicants to medical school are often encouraged to gain some exposure or experience of medicine. (Doctors' children traditionally already have some of this.) -While these informal requests are usually accommodated, there are important medicolegal issues to consider:+While these informal requests are usually accommodated, there are important medico-legal issues to consider: *Confidentiality. *Confidentiality. Line 12: Line 12: **Should they need a CRB? **Should they need a CRB? -If pupils cannot be easily accommodate, can suggest alternatives:+If pupils cannot be easily accommodated, can suggest alternatives: *No direct or minimal clinical contact, e.g. follow receptionist or helping with secretarial work (though caveats of confidentiality apply). *No direct or minimal clinical contact, e.g. follow receptionist or helping with secretarial work (though caveats of confidentiality apply). *Consider Baby clinics or other opportunities where patients are generally healthy and less likely to have embarrassing problems. *Consider Baby clinics or other opportunities where patients are generally healthy and less likely to have embarrassing problems. [...]



Safety net

Wed, 30 Nov 2016 15:18:24 GMT

Redirected page to Safety netting

New page

#REDIRECT [[Safety netting]]



Commissioning for Quality and Innovation (CQUINs) payments framework

Wed, 30 Nov 2016 14:57:09 GMT

← Older revision Revision as of 14:57, 30 November 2016
(One intermediate revision not shown)
Line 3: Line 3:
:''"The Commissioning for Quality and Innovation (CQUINs) payments framework encourages care providers to share and continually improve how care is delivered and to achieve transparency and overall improvement in healthcare."''
:''"The Commissioning for Quality and Innovation (CQUINs) payments framework encourages care providers to share and continually improve how care is delivered and to achieve transparency and overall improvement in healthcare."''
 +
 +
{{England|[https://www.england.nhs.uk/nhs-standard-contract/cquin/cquin-16-17/ Information about 2016/17 CQUIN from NHS England.]}}